Will Verastem Make You Vera-Rich?
Published: Sep 13, 2017
If you follow Verastem (NASDAQ:VSTM), you probably know that they've had a very good 2017, going from $1.14 to open the year up to $5.40 as of me writing this. An article by Jonathan Faison called Verastem Outlook Post Duo Results does an excellent job explaining VSTM's phase 3 trial data for Duvelisib (DUO for short), so I won't rehash that. What I've been thinking about recently is trying to get some sort of valuation for VSTM.